Impact of a Shielded Safety Syringe on Needlestick Injuries Among Healthcare Workers

Abstract

These results suggest that shielded syringes and related technology may offer potential for reducing the risk of needlestick injuries among hospital and other healthcare employees. This study should be viewed as a preliminary effort to assess the potential of shielded-syringe technology for reducing the risk of needlestick injuries among healthcare workers. The results are encouraging, but more clinical experience with this new device and longer follow up are essential to provide the data necessary for a definitive assessment of efficacy.

Impact of safety needle devices on occupationally acquired needlestick injuries: a four-year prospective study

“…6 Several studies have attributed a reduction in the number of NSIs to innovative technologies that have produced needle protective devices. 7,8 However, Mulherin et al reported that many staff considered some safety needles to be unsatisfactory, and that over 40% of the devices had not had their safety feature activated on disposal. 9 The Occupational Safety and Health Administration highlighted that a comprehensive training programme is required before needle protective devices are introduced in order to ensure that they are accepted by healthcare workers.…”

Safety Syringes and Anti-Needlestick Devices in Orthopaedic Surgery

“…The candidate safety technologies were identified through a review of the literature and educational safety resources [22][23][24][25][26][27][28][29][30][31] . Candidate technologies included safety needles, retractable syringes, shielded syringes, and mechanical syringes [27][28][29][30][31][32][33][34][35][36][37][38] . The devices initially were tested ex vivo and were used in clinical practice to obtain experience with the idiosyncrasies of each device.…”

Cost-Effectiveness of Therapeutic Use of Safety-Engineered Syringes in Healthcare Facilities in India

“…For care sought in public health facilities, we considered both the health system cost and OOPE for treatment. The health system cost of treatment was accessed from the national health system cost database as well as from other costing studies [22,31,[33][34][35][36][37]. In the case of treatment from the private sector, the OOPE was considered to capture the full cost.…”

“…One study with a large sample size and of high quality that reported the impact of SES on NSI rate per 100 injections was considered appropriate for use in the decision model (relative risk 0.12; 95% CI 0.04-0.41) [35].…”